| nazwa = Klasyfikacja ATC/L04
| tytuł = [[ATC (L04)|L04]]: Leki immunosupresyjne
| zwijanie = zwinięte
| opis1 = L04A – Leki immunosupresyjne
| opis1.1 = L04AA – Selektywne leki immunosupresyjne
| spis1.1 =
* [[kwas mykofenolowy]]
* [[alefacept]]
* [[gusperimus]]
* [[efalizumab]]
* [[abetimus]]
* [[abatacept]]
* [[belatacept]]
* [[apremilast]]
* [[kladrybina]]
* [[imlifidaza]]
* [[belumosudyl]]
* [[efgartigimod alfa]]

| opis1.10 = L 04 AK – Inhibitory [[dehydrogenaza dihydroorotanowa|dehydrogenazy<br /> dihydroorotanowej]] (DHODH)
| spis1.10 =
* [[leflunomid]]
* [[teryflunomid]]

| opis1.11 = L04AX – Inne
| spis1.11 =
* [[azatiopryna]]
* [[talidomid]]
* [[metotreksat]]
* [[lenalidomid]]
* [[pirfenidon]]
* [[pomalidomid]]
* [[fumaran dimetylu]]
* [[darwadstrocel]]
* [[fumaran diroksymelu]]

| opis1.2 = L04AB – Inhibitory TNF-α
| spis1.2 =
* [[etanercept]]
* [[infliksymab]]
* [[adalimumab]]
* [[certolizumab pegol]]
* [[golimumab]]
* [[opinercept]]

| opis1.3 = L04AC – Inhibitory interleukin
| spis1.3 =
* [[daklizumab]]
* [[bazyliksymab]]
* [[anakinra]]
* [[rylonacept]]
* [[ustekinumab]]
* [[tocilizumab]]
* [[kanakinumab]]
* [[briakinumab]]
* [[sekukinumab]]
* [[siltuksymab]]
* [[brodalumab]]
* [[iksekizumab]]
* [[sarylumab]]
* [[syrukumab]]
* [[guselkumab]]
* [[tyldrakizumab]]
* [[ryzankizumab]]
* [[satralizumab]]
* [[netakimab]]
* [[bimekizumab]]
* [[spesolimab]]
* [[olokizumab]]
* [[mirikizumab]]
* [[lewilimab]]

| opis1.4 = L04AD – Inhibitory kalcyneuryny
| spis1.4 =
* [[cyklosporyna]]
* [[takrolimus]]
* [[woklosporyna]]

| opis1.5 = L 04 AE – Modulatory [[receptor sfingozyno-1-fosforanu (S1P)|receptorów <br />sfingozyno-1-fosforanu (S1P)]]
| spis1.5 =
* [[fingolimod]]
* [[ozanimod]]
* [[siponimod]]
* [[ponesimod]]
* [[etrasymod]]

| opis1.6 = L 04 AF – Inhibitory [[kinazy janusowe|kinazy janusowej]] (JAK)
| spis1.6 =
* [[tofacytynib]]
* [[barycytynib]]
* [[upadacytynib]]
* [[filgotynib]]
* [[itacytynib]]
* [[peficytynib]]
* [[deukrawacytynib]]
* [[ritlecytynib]]

| opis1.7 = L 04 AG – [[Przeciwciała monoklonalne]]
| spis1.7 =
* [[muromonab-CD3]]
* [[afelimomab]]
* [[natalizumab]]
* [[belimumab]]
* [[wedolizumab]]
* [[alemtuzumab]]
* [[begelomab]]
* [[okrelizumab]]
* [[emapalumab]]
* [[inebilizumab]]
* [[anifrolumab]]
* [[ofatumumab]]
* [[teprotumumab]]
* [[ublituksymab]]
* [[diwozylimab]]
* [[rozanoliksyzumab]]

| opis1.8 = L 04 AH – Inhibitory [[kinaza mTOR|kinazy mTOR]]
| spis1.8 =
* [[sirolimus]]
* [[ewerolimus]]

| opis1.9 = L 04 AJ – Inhibitory [[dopełniacz (biologia)|dopełniacza]]
| spis1.9 =
* [[ekulizumab]]
* [[rawulizumab]]
* [[pegcetakoplan]]
* [[sutymlimab]]
* [[awakopan]]
* [[zilukoplan]]
* [[krowalimab]]
* [[iptakopan]]
* [[danikopan]]

| dół =
* [[Leki immunosupresyjne]]

| kategoria = leki w klasyfikacji ATC|L04